• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Bigfoot Biomedical

Bigfoot Biomedical appoints commercial team

December 9, 2020 By Sean Whooley

Bigfoot Biomedical updated logo

Bigfoot Biomedical announced today that it established a team led by Berkley Nelson to lead the company’s sales effort. Bigfoot is marketing its the recently FDA-cleared Bigfoot Unity real-time, dose-decision support system, which uses smartpen caps and integrates Abbott’s FreeStyle Libre 2 continuous glucose monitoring platform. Get the full story at our sister site, MassDevice.

Filed Under: Business/Financial News, Diabetes, Drug-Device Combinations, Featured Tagged With: Bigfoot Biomedical, Personnel, Personnel Moves

Former Eli Lilly researcher joins Bigfoot Biomedical as chief medical officer

June 12, 2020 By Chris Newmarker

Bigfoot Biomedical updated logo

Bigfoot Biomedical has brought on Dr. Jim Malone — a 21-year clinical research veteran at Eli Lilly & Co. — as its chief medical officer, the diabetes treatment tech company said today. Malone, an endocrinologist specializing in diabetes, also spent 12 years in clinical practice. “Jim’s blended experience in medical practice and device development bring […]

Filed Under: Business/Financial News, Diabetes, Drug-Device Combinations, Featured Tagged With: Bigfoot Biomedical, Personnel Moves

Bigfoot Biomedical raises $55m in Series C

June 3, 2020 By Sean Whooley

Bigfoot Biomedical updated logo

Diabetes treatment tech company Bigfoot Biomedical announced today that it raised $55 million to close its Series C financing round. Abbott (NYSE:ABT) led the funding round with participation from new investor Smile Group and existing investors Quadrant Capital Advisors, Senvest Capital, Janus Henderson and Cormorant Asset Management. Get the full story at our sister site, MassDevice.

Filed Under: Business/Financial News, Diabetes, Drug-Device Combinations, Funding Roundup, Patient Monitoring Tagged With: abbott, Bigfoot Biomedical

Abbott boosts support for Bigfoot Biomedical and its diabetes treatment tech

January 13, 2020 By Chris Newmarker

Bigfoot Biomedical Abbott Bigfoot Unity diabetes management program

Diabetes treatment tech company Bigfoot Biomedical has raised another $45 million in the initial tranche of a Series C equity financing, with collaborator Abbott (NYSE:ABT)  as the lead investor. “We are excited to announce Abbott’s deepening support of Bigfoot Biomedical with this Series C financing,” Bigfoot Biomedical CEO Jeffrey Brewer said in a news release today.  […]

Filed Under: Business/Financial News, Diabetes, Drug-Device Combinations, Featured Tagged With: abbott, Abbott Laboratories, artificial pancreas, Bigfoot Biomedical, insulin

Bigfoot Biomedical inks deal with Pittsburgh health system

August 1, 2019 By Nancy Crotti

Bigfoot Biomedical updated logo

Bigfoot Biomedical today announced an agreement with Pittsburgh-based Allegheny Health Network (AHN) to further develop Bigfoot’s Unity investigational insulin delivery wireless platform. The diabetes startup described Unity as a first-in-kind, data-driven solution for optimizing insulin dosing and delivery. Bigfoot will work alongside AHN endocrinologists and primary care doctors to refine Unity’s clinical workflow features. “We understand […]

Filed Under: Business/Financial News, Diabetes, Drug-Device Combinations, Featured, Patient Monitoring, Research & Development, Uncategorized Tagged With: Allegheny Health Network, Bigfoot Biomedical

Bigfoot Biomedical, Owen Mumford ink deal for pen needles

February 7, 2019 By Sarah Faulkner

Bigfoot Biomedical updated logo

Bigfoot Biomedical said today that it inked a commercial supply deal to include Owen Mumford‘s Pentips line of pen needles with Bigfoot’s injection system subscription bundles. Milpitas, Calif.-based Bigfoot is working on monthly subscription packages for people with insulin-requiring diabetes. The company said it selected Owen Mumford’s pen needle because of the needle’s compatibility with […]

Filed Under: Business/Financial News, Diabetes, Drug-Device Combinations, Featured, Pharmaceuticals Tagged With: Bigfoot Biomedical, owenmumford

Bigfoot Biomedical inks insulin deal with Eli Lilly

January 7, 2019 By Sarah Faulkner

Bigfoot Biomedical updated logo

Bigfoot Biomedical said today that it inked a non-exclusive deal with Eli Lilly (NYSE:LLY) to integrate Eli Lilly’s insulin products into Bigfoot’s investigational insulin delivery devices. The California-based company expects to launch its first two insulin delivery systems – Bigfoot Inject and Bigfoot Loop – in 2020, contingent upon finishing a pivotal trial and landing regulatory […]

Filed Under: Business/Financial News, Diabetes, Drug-Device Combinations, Featured, Pharmaceuticals, Wall Street Beat Tagged With: abbott, Bigfoot Biomedical, Eli Lilly & Co.

How Bigfoot Biomedical’s CEO wants to boost diabetes management

May 8, 2018 By Sarah Faulkner

Jeffrey Brewer at DeviceTalks

Jeffrey Brewer faced the biggest challenge of his life when his 7-year-old son Sean received a diabetes diagnosis in 2002: Diabetes became the new focus for Brewer’s energy. In his role as CEO at JDRF (formerly the Juvenile Diabetes Research Foundation) between 2011 and 2014, Brewer forged financial partnerships with industry to drive the development […]

Filed Under: Diabetes, Drug-Device Combinations, Featured, Pharmaceuticals Tagged With: Bigfoot Biomedical, devicetalksminnesota

Bigfoot brings Series B total to $55m with new investment from Abbott

March 28, 2018 By Sarah Faulkner

Bigfoot Biomedical

Reeling in an $18 million add-on to the $37 million Series B that it reported last year, Bigfoot Biomedical touted today that it has raised over $90 million in total funding since the Milpitas, Calif.-based company first launched. Investments from Abbott (NYSE:ABT), which has an established partnership with Bigfoot, and other new and existing investors, brought the […]

Filed Under: Diabetes, Drug-Device Combinations, Featured, Funding Roundup, Pharmaceuticals, Wall Street Beat Tagged With: abbott, Bigfoot Biomedical

SFC Fluidics inks deal with JDRF to develop automated insulin delivery system

January 22, 2018 By Sarah Faulkner

SFC Fluidics

SFC Fluidics has inked a two-year deal with JDRF to develop an automated insulin delivery system that combines a continuous glucose monitor and an insulin delivery algorithm into a single disposable device. JDRF is slated to provide funding to the medical device company as part of its Artificial Pancreas Project, which aims to accelerate the […]

Filed Under: Diabetes, Drug-Device Combinations, Featured, Pharmaceuticals, Research & Development Tagged With: Bigfoot Biomedical, Juvenile Diabetes Research Foundation (JDRF), Medtronic, sfcfluidics

  • Go to page 1
  • Go to page 2
  • Go to page 3
  • Go to Next Page »

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Tweets by DrugDeliveryNow

Footer

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Design & Outsourcing
Medical Tubing + Extrusion

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery News
Advertise with us
About
Contact us
Privacy
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2021 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS